Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL650853 | 0.96 | AGTR2 (0.43) | AGTR2AGTR1 | |
| SCHEMBL656869 | 0.96 | AGTR2 (0.43) | AGTR2AGTR1 | |
| SCHEMBL656868 | 0.96 | AGTR2 (0.43) | AGTR2AGTR1 | |
| SCHEMBL652670 | 0.93 | AGTR2 (0.42) | AGTR2AGTR1 | |
| SCHEMBL994431 | 0.92 | AGTR2 (0.45) | AGTR2AGTR1 | |
| SCHEMBL653073 | 0.92 | AGTR2 (0.45) | AGTR2AGTR1 | |
| SCHEMBL656488 | 0.92 | AGTR2 (0.50) | AGTR2 | |
| SCHEMBL650654 | 0.91 | AGTR2 (0.43) | AGTR2AGTR1 | |
| SCHEMBL671768 | 0.91 | AGTR2 (0.47) | AGTR2AGTR1 | |
| SCHEMBL652375 | 0.91 | AGTR2 (0.49) | AGTR2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220016219-A1 | Means and Methods to Treat Diabetes | EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET (DE) | 2022-01-20 | — | — | US | claimed |
| WO-2020157264-A1 | IMPROVED MEANS AND METHODS TO TREAT DIABETES | EBERHARD KARLS UNIVERSITÄT TÜBINGEN MEDIZINISCHE FAKULTÄT (DE) | 2020-08-06 | — | — | WO | claimed |
| EP-3689367-A1 | IMPROVED MEANS AND METHODS TO TREAT DIABETES | Eberhard Karls Universität Tübingen Medizinische Fakultät (DE) | 2020-08-05 | — | — | EP | claimed |
| EP-3202494-B1 | PROCESS FOR EPOXIDATION AND CATALYST TO BE USED THEREIN | BASF SE (DE) | 2019-08-21 | — | — | EP | disclosed |
| EP-3202494-A1 | PROCESS FOR EPOXIDATION AND CATALYST TO BE USED THEREIN | BASF SE (DE) | 2017-08-09 | — | — | EP | disclosed |
| EP-2451782-B1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2016-11-09 | — | — | EP | disclosed |
| US-8822522-B2 | Dual-acting pyrazole antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130245041-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-09-19 | — | — | US | disclosed |
| US-8350027-B2 | Dual-acting pyrazole antihypertensive agents | THERAVANCE, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8119550-B2 | Zeolite; separation from mother liquor; roasting | BASF AKTIENGESELLSCHAFT (DE) | 2012-02-21 | — | — | US | disclosed |
| US-8119634-B2 | Dual-acting pyrazole antihypertensive agents | THERAVANCE, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| EP-1549433-A1 | IMPROVED CATALYST FOR EPOXIDATION REACTIONS | BASF AKTIENGESELLSCHAFT (DE) | 2005-07-06 | — | — | EP | disclosed |
| EP-1545771-A1 | PROCESS FOR EPOXIDATION AND CATALYST TO BE USED THEREIN | BASF AKTIENGESELLSCHAFT (DE) | 2005-06-29 | — | — | EP | disclosed |
| US-6884743-B2 | Catalyst for epoxidation reactions | BASF AKTIENGESELLSCHAFT (DE) | 2005-04-26 | — | — | US | disclosed |
| US-20050085646-A1 | Process for epoxidation and catalyst to be used therein | BASF AKTIENGESELLSCHAFT (DE) | 2005-04-21 | — | — | US | disclosed |
| US-20050054865-A1 | A mixture of titanium tetraalkoxide and alkylene diols the reaction product of which catalyzes the depolymerization of a blend polyesters to give a gel-free mixture of cyclic homopolymers free of any cyclic copolymers; purity; molding materials intermediates;auto paints | BASF AKTIENGESELLSCHAFT (DE) | 2005-03-10 | — | — | US | disclosed |
| WO-2004026467-A1 | PROCESS FOR EPOXIDATION AND CATALYST TO BE USED THEREIN | BASF AKTIENGESELLSCHAFT (DE) | 2004-04-01 | — | — | WO | disclosed |
| WO-2004024321-A1 | IMPROVED CATALYST FOR EPOXIDATION REACTIONS | BASF AKTIENGESELLSCHAFT (DE) | 2004-03-25 | — | — | WO | disclosed |
| US-20040053772-A1 | Crystallizing a zeolite solids comprising silica and titania, improving catalyst selectivity, for reacting propylene and hydrogen peroxide to propylene oxide | BASF AKTIENGESELLSCHAFT (DE) | 2004-03-18 | — | — | US | disclosed |
| US-20040054199-A1 | Process for epoxidation and catalyst to be used therein | BASF AKTIENGESELLSCHAFT (DE) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245041-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | AGTR2 2/4885AGTR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.